Clinical Trial

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Study acronym: NAD agent
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-04.
Trial Details
NCT Number NCT06866236
Lead Sponsor Ebima Clifford Okundaye
Conditions Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Enrollment 3,000 participants
Start Date 2025-10
Primary Completion 2026-10 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-08